A number of major players in the neurovascular device industry—including Medtronic, Microvention/Terumo and Penumbra—announced newly launched technologies throughout June. These updates, coupled with insights on recently published HEMERA-1 trial data, an exclusive interview with neurosurgeon Adnan Siddiqui, and a slew of new study results delivered across multiple global conferences, feature prominently among NeuroNews’ most-read stories from last month.
1. Medtronic unveils next-generation Artisse intrasaccular device alongside new data at LINNC Paris 2024
Medtronic has announced the European launch of Artisse—a new intrasaccular device designed to treat intracranial aneurysms by conforming to the shape of the aneurysm. The launch coincides with interim data that examine the safety, efficacy and performance of the device being presented for the first time at LINNC Paris 2024 (3–5 June, Paris, France).
2. Boston Scientific obtains CE mark for image-guided programming software in DBS
Boston Scientific Corporation has obtained a CE mark for the Vercise neural navigator 5 software with STIMVIEW XT technology, which—when used as part of the Vercise Genus deep brain stimulation (DBS) systems—can provide clinicians with simple and actionable data for efficient programming in the treatment of patients with Parkinson’s disease, essential tremor and dystonia.
3. NeuroOne announces first-in-human ablations completed with OneRF system
NeuroOne Medical Technologies Corporation has announced that the OneRF ablation system was recently used at a prestigious hospital located in Jacksonville, USA to successfully complete five ablations in one patient.
4. Positive HEMERA-1 data pave the way for further neuroprotection trials during ‘thrombectomy era’
Following the recent publication in Stroke: Vascular and Interventional Neurology of results from HEMERA-1, a prospective, multicentre trial evaluating the safety of novel neuroprotective agent PP-007 (Prolong Pharmaceuticals) alongside mechanical thrombectomy in acute stroke patients, lead investigator Italo Linfante (Miami Neuroscience Institute, Miami, USA) delves deeper into the data and discusses some of the study’s wider implications with NeuroNews.
5. PROFILE: Adnan Siddiqui
While he is a neurosurgeon by trade, Adnan Siddiqui (Buffalo, USA) has delved into an increasing number of domains throughout his career—not only through his interest in endovascular treatments and the neurosciences, but also via significant involvement in clinical trials, translational research, and even entrepreneurship. Here, the chief executive officer and chief medical officer of the Jacobs Institute, who is also a distinguished professor and vice-chairman of neurosurgery for the University at Buffalo, speaks to NeuroNews to chart his journey and provide insights on several major topics.
6. First-in-human data demonstrate Clotild smart guidewire can safely automate clot characterisation
Sensome has announced positive results from its first-in-human CLOT OUT clinical trial evaluating the safety and performance of the company’s Clotild smart guidewire system used during mechanical thrombectomy treatments for ischaemic stroke. The results showed that the technology met all primary safety and performance endpoints in the trial. There were no serious adverse events related to use of Clotild, and the device successfully automated the identification of red blood cells (RBCs) and platelets “in close alignment with human experts”, as noted in a Sensome press release.
7. Varied tenecteplase data may provide clarity on the drug’s exact role in acute stroke care
This year’s European Stroke Organisation Conference (ESOC; 15–17 May, Basel, Switzerland) saw a plethora of data on intravenous tenecteplase—from studies spanning Australia, Canada, China, Europe, and beyond—presented for the first time. Fresh findings from the ATTENTION-IA, ORIGINAL, TASTE, TEMPO-2 and TRACE III randomised controlled trials (RCTs) were disclosed, as were a combined analysis of data from the SWIFT DIRECT and EXTEND-IA TNK studies, and a meta-analysis of a total of nine already-published RCTs in this space.
8. Microvention announces US availability of LVIS EVO intraluminal support device
Microvention, a wholly owned subsidiary of Terumo Corporation, announced recently that the LVIS EVO intraluminal support device is now commercially available for the treatment of wide-neck intracranial aneurysms in the USA.
9. Patient selection may explain ‘counterintuitive’ relationship between carotid stenting volume and outcomes in new study
High stroke and death rates relating to carotid stenting in the Pacific Northwest of the USA may be driven by the selection of high-risk patients with less than 80% stenosis, and reducing the frequency of stenting in this high-risk group—along with better adherence to guideline-recommended medical management—could improve regional outcomes. This was among the key concluding messages from a retrospective review delivered during the 2024 Vascular Annual Meeting (VAM; 19–22 June, Chicago, USA).
10. Penumbra announces European launch of BMX81 and BMX96 neuro access offerings
Penumbra has announced the CE mark and European launch of BMX81 and BMX96—devices designed for the neurovascular management of ischaemic and haemorrhagic stroke. A company press release also notes that these technologies constitute Penumbra’s most advanced neuro access offerings.
